Volume 90 Issue 35 | p. 21 | Concentrates
Issue Date: August 27, 2012

Molecular Partners, Allergan Form Pacts

Department: Business
Keywords: protein drugs, collaboration, eye diseases

Molecular Partners and Allergan have two new agreements to discover and develop products for ophthalmic diseases. Allergan will pay the Swiss biotech firm $62.5 million up front and up to $1.4 billion in milestone payments. Molecular Partners develops small-protein drug candidates it calls DARPins. It will design a dual anti-VEGF-A/PDGF-B DARPin and related candidates for treating exudative age-related macular degeneration. The partners also will collaborate on finding DARPins against other eye-disease targets.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment